VRTX's Quality Score fell 1 point on Tue, Nov 10, to 16. It closed away from its high of the day (2 chart checks stopped).
Follow VRTX's trial news. Pro members can get an alert when Vertex Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 4% on Nov 3 while the S&P 500 rose 0.3%.
Up 188% over the five years to Nov 9 while the S&P 500 rose 72%; down 4% on Nov 3.
6 reasons, from its filings, with the timeline and its peers, for Pro members.
| Outperforming | Up 22% in 6 months vs the S&P's +2% |
| Latest filing | 10-Q, Nov 3 |
Mon Nov 16: UBS Global Biopharma Conference 2026Investor conference · date confirmed.
Expected to report Thu Feb 11, after the close
2 more dates ahead: conferences, for Pro members.
An officer, Ourania Tatsis, sold 1,500 shares on Jul 2, under a planned sale. 45 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Excellentfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
VRTX is #17 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 17 |
Net income over four quarters: VRTX $3.98B, MRK $2.45B.
Expected to report Thu Feb 11, after the close (in 93 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $3.4B, 12% more than a year ago; a profit of $2.56 a share, from $4.20.
“Total revenue increased 12% to $3.44 billion compared to the third quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies and growth from diversification into additional disease areas.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $3.4B | $3.3B | $3.1B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)
| Measure | Figure |
|---|---|
| Total revenue | $13.15B to $13.25B |
“The year-over-year decline is primarily due to expenses related to the Crinetics Pharmaceuticals acquisition.”
From its results filing (SEC filing · Nov 2)
Sales grew 14% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 0.4% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | +1.0% | -4.0% | -0.4% |
| Aug 3, 2026 | +0.1% | +1.7% | +11.3% |
| May 4, 2026 | +0.5% | -1.3% | +1.2% |
Sales grew every year from 2018 to 2025, to $12B. It turned a profit in 2025 after a loss in 2024.
RSI 57.8, MACD above signal, above both averages. Not scored.
20 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: VRTX is 1.6% of JEPI, 0.7% of JEPQ, and 0.7% of QQQI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
“The pharmaceutical industry is characterized by extensive research efforts, rapid technological progress, and intense competition.”
VRTX scores 16 today, which Breakaway calls Excellent. It is #17 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Down 4% on Nov 3 while the S&P 500 rose 0.3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
VRTX scores 16 today, which Breakaway calls Excellent (15 to 19). That is #17 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VRTX's 16.
Expected to report Thu Feb 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. VRTX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.